



Public Pharmacy Benefit Manager Transparency Report

2023 Data

7/31/2024

REPORT PREPARED BY:

Minnesota Department of Commerce
Insurance Division

85 7th Place East St. Paul, MN 55101

<https://mn.gov/commerce/insurance/>

Upon request, this material will be made available in an alternative format such as large print, Braille or audio recording. Printed on recycled paper.

Minnesota Department of Commerce

Mission

For more than 150 years, the Minnesota Department of Commerce and its predecessor agencies have served Minnesotans. Our mission is to protect and assist consumers, to ensure a strong, competitive and fair marketplace, and to engage people and communities across the state.

Our Strategic Priorities

- Protect the public interest through consumer protection, consumer education, assistance to consumers, safety, health and financial security, and lowering inequities.
- Serve as a trusted public resource for consumers and businesses by listening and learning from the Minnesotans Commerce services, being effective stewards of public resources, advocating for Minnesota consumers and develop a policy, programmatic, and regulatory environment that meets their needs.
- Reduce economic barriers within Commerce regulatory oversee and reduce disparities within those of all races, ethnicities, religions, economic statuses, gender identities, sexual orientations, (dis)abilities, and zip codes.
- Ensure all, especially historically disadvantaged Minnesotans, are resilient to Minnesota's climate and engaged in advancing efforts to mitigate climate change.
- Ensure a strong, competitive, and fair marketplace for Minnesotans.

For more about the Department of Commerce: mn.gov/commerce

Contents

Pharmacy Benefit Manager (PBM) Transparency Reporting4

 Reporting Process.....4

 Data Limitations.....4

Definitions of Key Terms5

PBM Transparency Public Reference Materials6

 Transparency Reporting FAQ.....6

 Claims Level Detail Template6

 Aggregate Report Template6

 Public Report Template7

PBM Public Transparency Report Submissions7

Pharmacy Benefit Manager (PBM) Transparency Reporting

Minn. Stat. § 62W.06 Subd. 2 requires all licensed PBMs to submit a transparency report, containing both aggregate and claims level data for the prior calendar year, to the Department of Commerce. Commerce is required to publish the public data contained in the PBM transparency reporting on its website.

Reporting Process

Instructions and three templates for reporting aggregate, claims level detail, and public data were made available on the Commerce website to all licensed PBMs.

PBMs were required to submit transparency reporting data to Commerce by June 1, 2024. Due to the varying nature of PBM business models and contracts, a given PBM may not be responsible for submitting a full report. PBMs claiming to be exempt from all reporting requirements were given the option to submit “zero” reports along with written rationale for the basis of their claim. A summary of the responses received by Commerce is shown in the table at the right.

As required by law, the public reports do not contain any information, such as claims level detail, that could lead to identification of a plan sponsor. To further protect plan sponsor identities, the public reports do not include the name of the submitting PBM.

Summary of responses from PBMs	
Total licensed PBMs	50
Public Reports submitted	28
Zero Reports submitted	20
PBMs not responding or missing reports	2

Data Limitations

- PBMs were given instructions regarding units, rounding, and calculated fields, but Commerce cannot guarantee full compliance with the reporting instructions.
- The data in this report has not been independently audited.
- While Commerce provided a data dictionary, PBM reporting may vary based on a PBM’s internal definitions of a given term.
- The public reports in this document are as submitted by the PBMs. Commerce has not vetted or modified the data, unless explicitly noted.

Definitions of Key Terms

WAC

The aggregate wholesale acquisition cost (WAC) of a given drug from the drug's manufacturer (does not include discounts or rebates).

Net WAC

WAC minus any rebates and other fees paid to the PBM with associated claims.

Non-Plan Sponsor

Refers to network pharmacies or pharmacies in which the PBM has a contractual relationship. For the purposes of the transparency report, data from non-plan sponsors excludes any fees assessed directly to plan sponsors (such as a per member per month fee or any other quantifiable monetary restriction applicable only to the plan sponsor).

Rebates

Defined in Minn. Stat. § 62W.02 Subd. 17 as all price concessions paid by a drug manufacturer to a pharmacy benefit manager or plan sponsor, including discounts and other price concessions that are based on the actual or estimated utilization of a prescription drug. Rebates also include price concessions based on the effectiveness of a prescription drug as in a value-based or performance-based contract.

Other fees and payments

The aggregate of all fees, attributable to claims in the given category, from all sources, indirect or direct, that the PBM receives for all PBM plan sponsor clients, except those defined as rebates above. Examples of fees include transaction fees, administrative fees, fees assessed to pharmacies, and claims payments from plan sponsors.

Total Rebates and Other Fees and Payments

Calculated as a sum of *total rebates* and *other fees and payments*.

Total Rebates and Other Fees and Payments – Non Plan Sponsor

Total amount of rebates and other fees and payments except those that come directly from plan sponsors.

Retained Rebates and Other Fees and Payments – Non Plan Sponsor

The total amount of rebates and other fees and payments, except those directly from plan sponsors, that are retained by the pharmacy benefit manager as revenue for services provided.

Retained Rebates and Other Fees and Payments Percentage – Non Plan Sponsor

The amount of rebates and other fees and payments, except those directly from plan sponsors, that are retained by the pharmacy benefit manager as revenue for services provided stated as a percentage of the total collected.

Therapeutic Category

The grouping of drugs based on similar characteristics such as chemical structure, mechanism of action, or disease treated. PBMs were instructed use the US Pharmacopeia (USP) classification system and report drug groupings at the category level.

Plan Sponsor

A group purchaser as defined under Minn. Stat. § 62J.03; an employer in the case of an employee health benefit plan established or maintained by a single employer; or an employee organization in the case of a health plan established or maintained by an employee organization, an association, joint board trustees, a committee, or other similar group that establishes or maintains the health plan. This term includes a person or entity acting for a pharmacy benefit manager in a contractual or employment relationship in the performance of pharmacy benefit management. Plan sponsor does not include the Minnesota Department of Human Services.

PBM Transparency Public Reference Materials

Supplementary materials related to the PBM Transparency Reporting can be found on the Department of Commerce's PBM webpage: <https://mn.gov/commerce/insurance/industry/pbm/>

These include the FAQ document for the 2023 reporting cycle and the three submission templates: claims level detail report, aggregate report, and public report.

Transparency Reporting FAQ

The transparency reporting FAQ was developed based on anticipated questions from PBMs on the reporting process, requirements, and parameters. The initial FAQ was submitted to all licensed PBMs on August 31, 2020, and then updated on September 21, 2020 based on feedback and questions received from PBMs. For the current 2023 data cycle, Commerce added an additional field to the FAQ to clarify that the Other Fees and Payments field in the aggregate reporting template includes claims amounts charged to plan sponsors.

Claims Level Detail Template

This document was developed in August 2020 and finalized in September 2020 after incorporating feedback from licensed PBMs and other stakeholders. The template requires PBMs to populate data at the individual claims level for enrollees of plan sponsors doing business in Minnesota. The data fields are based on the list of data required under Minn. Stat. § 62W.06 Subd. 2(7)(a)(i)-(x). No subsequent substantive changes have been made to the template.

Aggregate Report Template

This document was developed in August 2020 and finalized in September 2020 after incorporating feedback from licensed PBMs and other stakeholders. The template requires PBMs to populate data at the Therapeutic Category level and summarize a number of items regarding prescription drug prices, related rebates by therapeutic category, and overall wholesale acquisition costs for all plan sponsors doing business in Minnesota. The data fields are based on the list of data required under Minn. stat. § 62W.06 Subd. 2 (a)(1)-(6). For the current 2023 data cycle, Commerce added an additional field to the Definitions tab to clarify that the Other Fees and Payments field includes claims amounts charged to plan sponsors.

Public Report Template

This document was developed in September 2020 and finalized after receiving no feedback. The template contains data fields required under Minn. Stat. § 62W.06 Subd. 2 (b), forming public reports for each PBM. Beginning with 2021 data reporting, Commerce required PBMs to complete this template in addition to the Claims Level Detail and Aggregate Report Templates. No subsequent substantive changes have been made to the template.

PBM Public Transparency Report Submissions

The remainder of this report includes the public report submissions from PBMs.

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period								
Total	\$ 198,952	\$ -	\$ -	\$ -	\$ -	\$ -	0%	\$ 198,952

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
MIGRAINE PRODUCTS	\$ 69,739	\$ 69,739
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 54,430	\$ 54,430
ANTIPSYCHOTICS/ANTIMANIC AGENTS	\$ 11,277	\$ 11,277
ANALGESICS - OPIOID	\$ 11,155	\$ 11,155
ENDOCRINE AND METABOLIC AGENTS - MISC.	\$ 8,238	\$ 8,238
DERMATOLOGICALS	\$ 6,112	\$ 6,112
OPHTHALMIC AGENTS	\$ 4,600	\$ 4,600
ANALGESICS - ANTI-INFLAMMATORY	\$ 4,054	\$ 4,054
ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIA	\$ 3,988	\$ 3,988
CHEMICALS	\$ 3,739	\$ 3,739

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 175,000	\$ 20,000	\$ -	\$ 20,000	\$ -	\$ -	0%	\$ 155,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Analgesics	\$ 50,000	\$ 45,000
Respiratory Tract/Pulmonary Agents	\$ 25,000	\$ 21,000
Anesthetics	\$ 16,000	\$ 15,000
Anticonvulsants	\$ 15,000	\$ 13,000
Blood Products/Modifiers/Volume Expanders	\$ 13,000	\$ 10,000
Anti-Addiction/Substance Abuse Treatment Agents	\$ 13,000	\$ 11,000
Blood Glucose Regulators	\$ 13,000	\$ 11,000
Antivirals	\$ 8,000	\$ 8,000
MEDICAL DEVICES AND SUPPLIES	\$ 4,000	\$ 4,000
Ophthalmic Agents	\$ 4,000	\$ 4,000

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
15%	1%	8%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 9,264,849	\$ 3,712,178	\$ 270,975	\$ 3,946,969	\$ 3,761,842	\$ 345,278	9%	\$ 5,281,696

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 3,435,312	\$ 2,073,852
Blood Glucose Regulators	\$ 2,170,550	\$ 860,534
Blood Products and Modifiers	\$ 482,984	\$ 309,854
Antineoplastics	\$ 474,789	\$ 447,074
Anti-obesity Agents	\$ 427,831	\$ 245,369
Respiratory Tract/Pulmonary Agents	\$ 381,764	\$ 180,840
Dermatological Agents	\$ 351,247	\$ 181,206
Cardiovascular Agents	\$ 326,558	\$ 142,227
Central Nervous System Agents	\$ 279,687	\$ 211,535
Antimigraine Agents	\$ 190,505	\$ 102,559

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
15%	9%	13%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 874,714,000	\$ 46,500,000	\$ 673,915,000	\$ 720,415,000	\$ 46,575,000	\$ 6,896,000	15%	\$ 154,299,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 200,971,000	\$ 17,055,000
Blood Glucose Regulators	\$ 126,882,000	\$ 854,000
Antineoplastics	\$ 86,052,000	\$ 10,977,000
Respiratory Tract/Pulmonary Agents	\$ 56,818,000	\$ 2,015,000
Blood Products and Modifiers	\$ 55,136,000	\$ 338,000
Central Nervous System Agents	\$ 43,672,000	\$ 6,554,000
Anti-obesity Agents	\$ 38,599,000	\$ 5,020,000
Antivirals	\$ 26,678,000	\$ 5,086,000
Genetic, Enzyme, or Protein Disorder: Replacement, Mod	\$ 14,346,000	\$ 233,000
Cardiovascular Agents	\$ 46,461,000	\$ 33,183,000

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

	Highest	Lowest	Mean
n/a	0%	0%	0%

Note from PBM: The value of rebates received is provided back to sponsors through discounted pricing.

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 993,240	\$ 102,822	\$ (11,687)	\$ 91,135	\$ 91,135	\$ -	0%	\$ 902,105

Note from PBM: The value of rebates received is provided back to sponsors through discounted pricing.

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Analgesics	\$ 242,231	\$ 205,056
Immunological Agents	\$ 161,134	\$ 154,448
Anticonvulsants	\$ 65,408	\$ 65,951
Antibacterials	\$ 63,035	\$ 63,290
Skeletal Muscle Relaxants	\$ 50,633	\$ 51,448
Antimigraine Agents	\$ 45,185	\$ 36,155
Products Without a USP Category	\$ 43,165	\$ 36,363
Antivirals	\$ 37,076	\$ 37,236
Metabolic Bone Disease Agents	\$ 33,058	\$ 27,210
Blood Glucose Regulators	\$ 31,081	\$ 24,674

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 20,558,360	\$ 8,739,136	\$ -	\$ 8,739,136	\$ 8,739,136	\$ -	0%	\$ 11,819,225

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
TARGETED IMMUNOMODULATORS	\$ 9,178,599	\$ 4,994,002
ANTIDIABETICS	\$ 4,780,952	\$ 2,063,680
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 902,697	\$ 465,794
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	\$ 806,356	\$ 733,844
ANTICOAGULANTS	\$ 621,013	\$ 416,326
DERMATOLOGICALS	\$ 558,521	\$ 460,695
ANTIVIRALS	\$ 529,662	\$ 491,145
MEDICAL DEVICES	\$ 439,475	\$ 299,527
ENDOCRINE AND METABOLIC AGENTS - MISC.	\$ 372,189	\$ 167,221
ADHD/ANTI-NARCOLEPSY	\$ 320,894	\$ 255,707

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and
Payments Percentage Across All Plan
Sponsors

Highest	Lowest	Mean
45%	5%	18%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 184,692,000	\$ 62,423,000	\$ 6,172,000	\$ 68,595,000	\$ -	\$ -	0%	\$ 116,097,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
IMMUNOLOGICAL AGENTS	\$ 61,985,000	\$ 31,126,000
BLOOD GLUCOSE REGULATORS	\$ 28,369,000	\$ 11,352,000
ANTINEOPLASTICS	\$ 14,825,000	\$ 14,198,000
RESPIRATORY TRACT/PULMONARY AGENTS	\$ 14,437,000	\$ 10,736,000
CENTRAL NERVOUS SYSTEM AGENTS	\$ 10,467,000	\$ 6,344,000
MISCELLANEOUS THERAPEUTIC AGENTS	\$ 8,017,000	\$ 5,017,000
ANTIVIRALS	\$ 6,089,000	\$ 5,939,000
BLOOD PRODUCTS AND MODIFIERS	\$ 5,372,000	\$ 3,663,000
DERMATOLOGICAL AGENTS	\$ 4,072,000	\$ 3,117,000
CARDIOVASCULAR AGENTS	\$ 3,706,000	\$ 3,212,000

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
99%	1%	50%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 12,698,767	\$ 3,269,020	\$ 134,553	\$ 3,403,573	\$ 3,285,111	\$ 16,091	0%	\$ 9,295,193

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ANTIDIABETICS	\$ 3,136,299	\$ 3,127,502
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 1,388,426	\$ 1,380,387
ANTICOAGULANTS	\$ 1,098,194	\$ 1,091,317
ANTIPSYCHOTICS/ANTIMANIC AGENTS	\$ 1,039,072	\$ 1,032,672
PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS	\$ 584,771	\$ 583,303
DERMATOLOGICALS	\$ 543,412	\$ 539,731
HEMATOLOGICAL AGENTS - MISC.	\$ 507,911	\$ 482,242
ANALGESICS - ANTI-INFLAMMATORY	\$ 458,437	\$ 440,915
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	\$ 455,170	\$ 454,787
MEDICAL DEVICES AND SUPPLIES	\$ 269,698	\$ 266,988

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	79%	56%	22%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 626,375,000	\$ 249,335,000	\$ 30,460,000	\$ 279,798,000	\$ 279,798,000	\$ 30,460,000	11%	\$ 346,573,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ANALGESICS - ANTI-INFLAMMATORY	\$ 166,836,000	\$ 87,792,000
ANTIDIABETICS	\$ 123,612,000	\$ 49,352,000
DERMATOLOGICALS	\$ 119,192,000	\$ 62,660,000
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 31,205,000	\$ 13,386,000
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	\$ 26,732,000	\$ 24,329,000
ANTICOAGULANTS	\$ 20,377,000	\$ 13,324,000
ANTIVIRALS	\$ 18,975,000	\$ 16,114,000
PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	\$ 15,309,000	\$ 12,071,000
ENDOCRINE AND METABOLIC AGENTS - MISC.	\$ 14,609,000	\$ 7,011,000
ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS	\$ 12,858,000	\$ 9,229,000

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2023

Retained Rebates and Other Fees and Payments
Percentage Across All Plan Sponsors

Highest	Lowest	Mean
100%	0%	16%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 6,626,076	\$ 1,266,409	\$ 108,756	\$ 1,375,165	\$ 1,375,165	\$ 273,957	20%	\$ 5,250,911

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ANTIHYPERGLYCEMICS	\$ 1,042,819	\$ 607,425
ANTIINFLAM.TUMOR NECROSIS FACTOR INHIBITING AGENTS	\$ 888,893	\$ 634,468
ANTINEOPLASTICS	\$ 653,188	\$ 639,378
IMMUNOSUPPRESSANTS	\$ 451,508	\$ 313,501
PSYCHOTHERAPEUTIC DRUGS	\$ 407,028	\$ 372,137
ANTIARTHRITICS	\$ 354,121	\$ 250,463
SKIN PREPS	\$ 315,319	\$ 243,987
SEDATIVE/HYPNOTICS	\$ 223,375	\$ 212,343
ANTIASTHMATICS	\$ 212,988	\$ 159,724
EENT PREPS	\$ 186,441	\$ 176,746

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2023

Retained Rebates and Other Fees and Payments
Percentage Across All Plan Sponsors

Highest	Lowest	Mean
0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 3,038,000	\$ 588,000	\$ -	\$ 588,000	\$ -	\$ -	0%	\$ 2,449,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Antivirals	\$ 715,000	\$ 522,000
Blood Glucose Regulators	\$ 473,000	\$ 340,000
Central Nervous System Agents	\$ 412,000	\$ 344,000
Respiratory Tract/ Pulmonary Agents	\$ 182,000	\$ 159,000
Products Without a USP Category	\$ 161,000	\$ 106,000
Antipsychotics	\$ 140,000	\$ 120,000
Blood Products and Modifiers	\$ 126,000	\$ 99,000
Antimigraine Agents	\$ 120,000	\$ 95,000
Antidepressants	\$ 100,000	\$ 92,000
Hormonal Agents, Stimulant/ Replacement/ Modifying (Sex Hormones/ Hormones)	\$ 81,000	\$ 78,000

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2023

Retained Rebates and Other Fees and Payments
Percentage Across All Plan Sponsors

Highest	Lowest	Mean
51%	46%	48%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 146,961,000	\$ 46,013,000	\$ 2,451,000	\$ 48,464,000	\$ -	\$ -	0%	\$ 98,497,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 51,250,000	\$ 27,861,000
Blood Glucose Regulators	\$ 26,553,000	\$ 11,743,000
Respiratory Tract/Pulmonary Agents	\$ 11,574,000	\$ 9,283,000
Central Nervous System Agents	\$ 9,305,000	\$ 7,386,000
Antineoplastics	\$ 8,315,000	\$ 8,178,000
Blood Products and Modifiers	\$ 5,050,000	\$ 3,498,000
Cardiovascular Agents	\$ 3,174,000	\$ 3,044,000
Antivirals	\$ 3,046,000	\$ 2,946,000
Miscellaneous Therapeutic Agents	\$ 2,891,000	\$ 2,033,000
Dermatological Agents	\$ 2,576,000	\$ 2,160,000

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2023

**Retained Rebates and Other Fees and Payments
Percentage Across All Plan Sponsors**

Highest	Lowest	Mean
0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 21,182,088	\$ 3,180,614	\$ 22,589,680	\$ 25,770,294	\$ 3,180,614	\$ -	0%	\$ (7,768,820)

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Antidiabetics	\$ 5,887,051	\$ (2,833,091)
Analgesics - Anti-Inflammatory	\$ 3,831,235	\$ (1,026,713)
Dermatologicals	\$ 2,977,578	\$ (665,195)
Antineoplastics And Adjunctive Therapies	\$ 1,111,288	\$ (8,838)
Antiasthmatic And Bronchodilator Agents	\$ 913,435	\$ (569,652)
Psychotherapeutic And Neurological Agents - Misc.	\$ 694,065	\$ (13,374)
Anticoagulants	\$ 686,484	\$ (202,030)
Adhd/Anti-Narcolepsy/Anti-Obesity/Anorexiant	\$ 660,197	\$ (196,229)
Migraine Products	\$ 490,807	\$ (174,706)
Medical Devices And Supplies	\$ 450,876	\$ (318,034)

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2023

Retained Rebates and Other Fees and Payments
Percentage Across All Plan Sponsors

Highest	Lowest	Mean
0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 80,262	\$ 24,208	\$ 3,301	\$ 27,509				\$ 52,753

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ANTIDIABETICS	\$ 33,307	\$ 20,739
ANTICOAGULANTS	\$ 21,888	\$ 16,737
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 17,929	\$ 10,006
MIGRAINE PRODUCTS	\$ 3,396	\$ 2,398
MEDICAL DEVICES AND SUPPLIES	\$ 2,689	\$ 2,160
CONTRACEPTIVES	\$ 614	\$ 605
DIAGNOSTIC PRODUCTS	\$ 440	\$ 108

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2023

Retained Rebates and Other Fees and Payments
Percentage Across All Plan Sponsors

Highest	Lowest	Mean
100%	100%	100%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 2,761,137	\$ 429,534	\$ -	\$ 429,534	\$ 429,534	\$ 429,534	100%	\$ 2,331,602

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ANALGESICS - OPIOID	\$ 756,537	\$ 590,292
DERMATOLOGICALS	\$ 249,815	\$ 234,862
ANTICONVULSANTS	\$ 245,118	\$ 237,530
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 193,771	\$ 142,433
ANTIDEPRESSANTS	\$ 184,015	\$ 182,431
PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.	\$ 170,695	\$ 139,690
MIGRAINE PRODUCTS	\$ 141,875	\$ 96,809
MUSCULOSKELETAL THERAPY AGENTS	\$ 134,833	\$ 134,833
ANTICOAGULANTS	\$ 111,258	\$ 69,919
ANALGESICS - ANTI-INFLAMMATORY	\$ 104,402	\$ 104,402

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2023

Retained Rebates and Other Fees and Payments
Percentage Across All Plan Sponsors

Highest	Lowest	Mean
40%	0%	17%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 103,888,300	\$ 18,001,100	\$ 2,107,000	\$ 20,108,000	\$ 20,034,900	\$ 2,501,000	12.48%	\$ 83,780,600

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 42,382,500	\$ 33,781,500
Products Without USP Category	\$ 32,925,100	\$ 25,071,100
Antineoplastics	\$ 20,156,000	\$ 18,429,100
Anesthetics	\$ 2,328,100	\$ 1,238,200
Contraceptives	\$ 2,138,000	\$ 1,990,800
Blood Glucose Regulators	\$ 883,600	\$ 687,400
Central Nervous System Agents	\$ 792,600	\$ 593,900
Dermatological Agents	\$ 719,600	\$ 654,500
Gastrointestinal Agents	\$ 338,800	\$ 234,300
Antimigraine Agents	\$ 308,100	\$ 256,800

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
15%	15%	15%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 34,294,000	\$ 6,569,000	\$ -	\$ 6,569,000	\$ 6,569,000	\$ 985,000	15%	\$ 27,725,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 11,946,000	\$ 9,185,000
Blood Glucose Regulators	\$ 4,912,000	\$ 3,785,000
Respiratory Tract/Pulmonary Agents	\$ 2,473,000	\$ 1,993,000
Cardiovascular Agents	\$ 2,397,000	\$ 1,950,000
Blood Products and Modifiers	\$ 1,686,000	\$ 1,328,000
Central Nervous System Agents	\$ 1,540,000	\$ 1,264,000
Antineoplastics	\$ 1,211,000	\$ 1,056,000
Dermatological Agents	\$ 943,000	\$ 790,000
Antivirals	\$ 694,000	\$ 659,000
Anti-obesity Agents	\$ 541,000	\$ 452,000

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
56%	56%	56%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 187,581	\$ 1,084	\$ 86,052	\$ 87,136	\$ 1,084	\$ 604	56%	\$ 100,445

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Central Nervous System Agents	\$ 61,547	\$ 40,231
Analgesics	\$ 26,584	\$ 11,223
Antidepressants	\$ 21,456	\$ 9,577
Antispasticity Agents	\$ 12,694	\$ 10,645
Antipsychotics	\$ 11,239	\$ 10,811
Genitourinary Agents	\$ 8,024	\$ 5,138
Dermatological Agents	\$ 6,761	\$ 3,211
Anti-addiction/Substance Abuse Treatment Agents	\$ 4,530	\$ 2,566
Skeletal Muscle Relaxants	\$ 4,188	\$ 549
Antivirals	\$ 3,837	\$ (254)

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
13%	13%	13%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 18,612,781	\$ 2,468,031	\$ -	\$ 2,468,031	\$ 2,468,031	\$ 320,844	13%	\$ 16,144,750

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Interleukin Blockers	\$ 2,738,235	\$ 2,193,536
Blood Glucose Regulators	\$ 2,135,405	\$ 1,687,907
Tumor Necrosis Factor (TNF) Blockers	\$ 844,277	\$ 774,600
Factor Xa Inhibitors, Direct	\$ 838,453	\$ 804,546
Gallstone Solubilizing Agents	\$ 784,277	\$ 758,099
Imides	\$ 576,955	\$ 537,974
No USP PG, Bronchodilators, Combinations	\$ 501,601	\$ 501,601
Conductance Regulator Potentiators	\$ 426,140	\$ 374,011
Cyclin-dependent Kinase (CDK) Inhibitors	\$ 421,881	\$ 352,832
JAK Inhibitors	\$ 418,997	\$ 351,081

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
100%	0%	6%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 73,389	\$ 1,455	\$ 83,375	\$ 84,831	\$ 1,455	\$ 1,455	100%	\$ 155,309

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$ 40,281	\$ 80,722
ANTIDEPRESSANTS	\$ 12,304	\$ 26,235
DERMATOLOGICALS	\$ 5,669	\$ 11,428
OPHTHALMIC AGENTS	\$ 4,778	\$ 9,105
ANALGESICS - OPIOID	\$ 3,989	\$ 7,911
ULCER DRUGS	\$ 2,092	\$ 4,138
ANTICONSULSANTS	\$ 1,801	\$ 6,603
ANALGESICS - ANTI-INFLAMMATORY	\$ 596	\$ 2,229
MUSCULOSKELETAL THERAPY AGENTS	\$ 405	\$ 2,429
ENDOCRINE AND METABOLIC AGENTS - MISC.	\$ 260	\$ 529

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
1%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 706,390,262	\$ 222,029,639	\$ 657,681,852	\$ 879,711,491	\$ 208,050,573	\$ 399	0%	\$ (173,321,229)

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Antirheumatic	\$ 102,093,739	\$ (35,717,628)
Incretin Mimeti	\$ 100,681,849	\$ (39,590,251)
Skin And Mucous	\$ 74,547,007	\$ (22,931,901)
Antineoplastic	\$ 41,835,772	\$ (3,283,930)
Antiretrovirals	\$ 37,500,390	\$ (2,812,101)
Insulins	\$ 30,309,299	\$ (17,768,904)
Antidiabetic	\$ 22,004,686	\$ (11,025,759)
Anticoagulants	\$ 17,798,659	\$ (4,723,247)
Adrenals	\$ 15,302,907	\$ (4,530,885)
Amphetamines	\$ 12,556,744	\$ (2,283,527)

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC*
Totals During Data Period	\$ 8,579,595	\$ 732,080	\$ 2,736,269	\$ 3,013,101	\$ 3,013,101	\$ -	0%	\$ 5,566,495

* Net WAC for this PBM was calculated by Commerce from the WAC and Total Rebates and Other Fees and Payments amounts reported by the PBM.

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Disease-modifying Antirheumatic Drugs	\$ 1,044,006	\$ 101,042
Antidepressants	\$ 855,441	\$ 4,778
HMG-CoA Reductase Inhibitors	\$ 671,331	
Skin and Mucous Membrane Agents, Misc	\$ 473,229	\$ (1,963)
Incretin Mimetics	\$ 384,203	\$ 44,523
Antineoplastic Agents	\$ 279,188	\$ 21,152
Insulins	\$ 266,807	\$ 18,521
Proton-pump Inhibitors	\$ 253,474	
Anticonvulsants, Miscellaneous	\$ 248,599	\$ 2,765
Antipsychotics	\$ 203,005	\$ 4,516

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
52%	-7500%	-199%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 3,460,133,000	\$ 958,213,000	\$ 2,979,920,000	\$ 3,938,159,000	\$ 963,020,000	\$ 153,052,000	16%	\$ (478,057,000)

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
MISCELLANEOUS	\$ 570,754,000	\$ (60,713,000)
DIABETIC THERAPY	\$ 559,570,000	\$ (225,114,000)
ANTIARTHRITICS	\$ 514,862,000	\$ (125,864,000)
ANTINEOPLASTICS	\$ 260,168,000	\$ 4,204,000
ALL OTHER DERMATOLOGICALS	\$ 219,750,000	\$ (33,311,000)
ALL OTHER ANTI OBESITY PREPS	\$ 175,156,000	\$ (33,837,000)
ANTIVIRALS	\$ 133,989,000	\$ (2,627,000)
BRONCHIAL DILATORS	\$ 88,139,000	\$ (28,846,000)
ANTICOAGULANTS	\$ 84,174,000	\$ (7,927,000)
NON-OPIOID ANALGESICS	\$ 78,052,000	\$ (12,503,000)

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
25%	0%	4%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 44,110,613	\$ 10,646,614	\$ 240,671	\$ 10,887,285	\$ 10,646,614	\$ 1,184,816	11%	\$ 33,223,328

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	\$ 6,843,996	\$ 4,714,624
ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEPTOR AGONIST)	\$ 2,934,636	\$ 1,704,169
MONOCLONAL ANTIBODY-HUMAN INTERLEUKIN 12/23 INHIB	\$ 2,629,773	\$ 1,656,490
ANTIPSORIATIC AGENTS,SYSTEMIC	\$ 2,378,675	\$ 1,637,698
INSULINS	\$ 1,792,939	\$ 680,412
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	\$ 1,493,086	\$ 1,447,026
AGENTS TO TREAT MULTIPLE SCLEROSIS	\$ 1,064,736	\$ 981,914
ANTI-OBESITY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST	\$ 1,037,869	\$ 529,642
DIABETIC SUPPLIES	\$ 927,237	\$ 585,214
DIRECT FACTOR XA INHIBITORS	\$ 879,658	\$ 666,353

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 664,600	\$ -	\$ -	\$ -	\$ -	\$ -	0%	\$ 664,600

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Analgesics	\$ 378,800	\$ 378,800
Anticonvulsants	\$ 57,100	\$ 57,100
Antidepressants	\$ 36,200	\$ 36,200
Gastrointestinal Agents	\$ 36,100	\$ 36,100
Ophthalmic Agents	\$ 35,000	\$ 35,000
Dermatological Agents	\$ 27,300	\$ 27,300
Anesthetics	\$ 22,500	\$ 22,500
Antivirals	\$ 18,300	\$ 18,300
Blood Glucose Regulators	\$ 13,000	\$ 13,000
Blood Products and Modifiers	\$ 11,400	\$ 11,400

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 938	\$ 198	\$ 518	\$ 716	\$ -	\$ 24	0%	\$ 223

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
VIRAL VACCINES	\$ 476	\$ 106
AMPHETAMINES	\$ 369	\$ 172
COMBINATION CONTRACEPTIVES - ORAL	\$ 76	\$ (72)
ANTIHYPERTENSIVE COMBINATIONS	\$ 17	\$ 17

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

CY2023

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
0%	0%	0%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 416,982,533	\$ 89,989,684	\$ -	\$ 89,989,684	\$ 89,989,684	\$ -		\$ 326,992,848

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 132,036,545	\$ 100,185,958
Blood Glucose Regulators	\$ 55,360,174	\$ 32,430,498
Antineoplastics	\$ 31,177,281	\$ 30,310,766
Anti-obesity Agents	\$ 30,718,488	\$ 21,821,105
Respiratory Tract/Pulmonary Agents	\$ 25,069,731	\$ 19,219,905
Central Nervous System Agents	\$ 21,655,477	\$ 12,216,080
Blood Products and Modifiers	\$ 19,536,034	\$ 17,270,052
Dermatological Agents	\$ 12,992,853	\$ 11,485,084
Antivirals	\$ 8,381,226	\$ 8,111,071
Antimigraine Agents	\$ 7,463,930	\$ 5,933,421

Data for Publication on Commissioner Website
Masked PBM ID
Data Period

CY2023

Retained Rebates and Other Fees and Payments
Percentage Across All Plan Sponsors

Highest	Lowest	Mean
100%	0%	76%

	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
Totals During Data Period	\$ 1,307,180	\$ 230,777	\$ 764,493	\$ 995,270	\$ 269,541	\$ 204,520	75.88%	\$ 311,910

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 351,667	\$ (86,103)
Antineoplastics	\$ 167,050	\$ 30,491
Antidepressants	\$ 136,263	\$ 105,308
Cardiovascular Agents	\$ 120,939	\$ 97,910
Blood Glucose Regulators	\$ 99,678	\$ (18,166)
Analgesics	\$ 51,993	\$ 6,728
Products Without a USP Category	\$ 50,127	\$ 960
Anticonvulsants	\$ 42,994	\$ 25,586
Respiratory Tract Agents	\$ 42,429	\$ 12,676
Gastrointestinal Agents	\$ 38,085	\$ 32,182